Missouri has demonstrated remarkable commitment to our veterans with the ratification of SB 664 on July 14, 2025.  The “Veterans Traumatic Brain Injury Treatment and Recovery Act,” was passed with overwhelming support of 33-0 in the Senate and 156-1 in the House. Governor Mike Kehoe signed this groundbreaking legislation on Monday, establishing a fund to reimburse HBOT facilities treating veterans with TBI or PTSD, recognizing the treatment’s potential to combat veteran suicide and opioid addiction. The initiative represents a projected investment exceeding $5 million annually, underscoring the state’s confidence in this therapeutic approach.

HBOT works by delivering 100% oxygen in pressurized chambers at 1.4-3 times normal atmospheric pressure, dramatically increasing oxygen delivery to damaged brain tissues. Advocates report that this treatment “stimulates brain wound healing and can reverse soft tissue and neurocognitive damage” without requiring invasive surgery or pharmaceutical interventions. Patients can “experience recovery of cognitive and neurological functioning” through this non-invasive approach.

Clinical research has yielded encouraging results across multiple studies. For moderate-to-severe TBI cases, several high-quality studies demonstrated statistically significant improvements in consciousness recovery compared to standard care alone. Research has consistently shown better Glasgow Outcome Scale scores and reduced mortality rates in HBOT treatment groups. A comprehensive 2016 review highlighted that “most successes occurred within hours after TBI,” emphasizing the importance of early intervention. Particularly compelling evidence comes from pediatric research, where a study of 56 children with severe TBI found that HBOT “significantly improved quality of life and reduced complications” compared to control groups. Additional research involving 56 patients showed “significant improvement in symptoms and increased brain activity” measurable through SPECT brain imaging.

The treatment maintains a generally acceptable safety profile, with most side effects being minor and temporary, including ear discomfort, headaches, and fatigue. Serious adverse events remain rare when HBOT is properly administered. This positive safety record, combined with growing clinical evidence and strong legislative support, has led some VA facilities to begin offering HBOT treatment to veterans, representing an important step toward broader acceptance of this promising therapeutic intervention.